Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts of two clinical studies ...
Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced translational data from the GOBLET and AWARE-1 trials will be ...
Key Points Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better. CRB-701 will get more ...
Highlighted research being presented at the 2026 ASCO Annual Meeting includes breast, colorectal, lung, endometrial and renal ...
Investor Relations Event Details: Legend Biotech will host an in-person investor relations event on Sunday, May 31, 2026, at 6:15 p.m. CT (7:15 p.m. ET) during the American Society of Clinical ...
The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of Clinical Oncology conference largely isn’t reflecting that turmoil. In fact ...
Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
FOSTER CITY, Calif. & SANTA MONICA, Calif.-- (BUSINESS WIRE)--May 21, 2026-- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results